80.56 0.00 (0.00%)
After hours: 4:27PM EDT
|Bid||80.36 x 800|
|Ask||81.07 x 1300|
|Day's Range||79.13 - 80.63|
|52 Week Range||61.05 - 82.25|
|Beta (3Y Monthly)||1.07|
|PE Ratio (TTM)||27.48|
|Earnings Date||Jul 25, 2019|
|Forward Dividend & Yield||0.88 (1.20%)|
|1y Target Est||82.93|
Baxter International Inc. (BAX), a global innovator in renal care, showcased 19 data presentations on therapy options at the 56th ERA-EDTA Congress, Budapest, Hungary, June 13-16. The presentations spanned the renal care continuum, from chronic kidney disease (CKD) management to peritoneal dialysis (PD) and hemodialysis (HD).
Baxter (BAX) expects its bottom line to rise in the second quarter of 2019, courtesy to Renal Care and Clinical Nutrition businesses.
Baxter (BAX) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Baxter International Inc. (BAX), a global innovator in renal care, today announced receipt of a major research and development (R&D) grant from the German Federal Ministry of Education and Research (BMBF)’s “From Material to Innovation” program to lead a consortium investigating an anticoagulation-free hemodialysis (HD) option for end-stage renal disease (ESRD) patients. The grant provides €1.5 million in funding over three years to Baxter’s research team in Hechingen, Germany, and the consortium partners to find a solution that will improve health-related, quality-of-life outcomes for the millions of patients receiving HD therapy globally.
Concerns over rising interest rates and expected further rate increases have hit several stocks hard during the fourth quarter. Trends reversed 180 degrees during the first quarter amid Powell's pivot and optimistic expectations towards a trade deal with China. Hedge funds and institutional investors tracked by Insider Monkey usually invest a disproportionate amount of their […]
Baxter International Inc NYSE:BAXView full report here! Summary * Perception of the company's creditworthiness is neutral * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is extremely low for BAX with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting BAX. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding BAX totaled $79.78 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swap | NeutralThe current level displays a neutral indicator. BAX credit default swap spreads are near their highest levels of the last 3 years, which indicates the market's more negative perception of the company's credit worthiness.Please send all inquiries related to the report to firstname.lastname@example.org.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Baxter International Inc. (BAX), a leading global medical products company, will host a conference call to discuss its second quarter 2019 financial results on Thursday, July 25, 2019, at 7:30 a.m. Central Time. The Conference ID is 2089733.
DEERFIELD, Ill.-- -- Enhancements designed to give healthcare providers access to more comprehensive treatment data and improve clinic workflow New study further supports value of remote patient management technology to personalize dialysis treatments, reduce alarms and in-person visits, while saving clinicians and patients significant time Baxter International Inc. , a global innovator in renal care, ...
Baxter International Inc. (NYSE:BAX), a large-cap worth US$40b, comes to mind for investors seeking a strong and...
The Baxter International Foundation, the philanthropic arm of Baxter International Inc. (BAX), announced today a $2.2 million grant to Operation Smile, one of the world’s largest volunteer-based surgical nonprofit organizations, to deliver free surgical and multidisciplinary care to underserved communities in India. During the next three years, the grant will support Operation Smile’s year-round care centers in Mumbai, Srinagar and Bangalore—operated in partnership with the Inga Health Foundation—along with a new care center in Durgapur, West Bengal.
Baxter International Inc. (BAX), a global leader in acute care therapies, announced today that the peer-reviewed journal Blood Purification published a supplemental issue sponsored by Baxter that features real-world clinical experience with the company’s Oxiris filter, which can be used simultaneously in continuous renal replacement therapy (CRRT) and in the removal of cytokines and endotoxin to aide in the management of acute kidney injury (AKI) patients with sepsis. The studies, which are being highlighted at the 37th Vicenza Course on AKI and CRRT in Italy this week, add to the body of scientific knowledge around the use of extracorporeal (outside the body) blood purification (EBP) to address critical conditions.
Baxter (BAX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Synchrony Financial announced before the opening bell Thursday that it will increase its quarterly dividend by a penny, following dividend increases by Phillips 66 and Baxter International.
Baxter International Inc. (BAX), a leading global medical products company, today announced that representatives of the company will conduct a series of Fixed Income Investor Presentations on Thursday, May 9, 2019.
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Many investors are still learning about the various metrics that can be useful when analysing a stock...
Baxter International Inc. (BAX), a leading global medical products company, announced today that it has been named a 2019 Best Company for Multicultural Women by Working Mother magazine. This recognition is a result of the company’s sustained focus on supporting and advancing multicultural women at all levels of the organization globally.
Baxter International Inc. , a leading global medical products company, today announced an increase in the company’s quarterly cash dividend, to a rate of $0.22 per share of common stock.
Baxter International Inc. (BAX), a leading global medical products company, will present at the UBS Global Healthcare Conference on Monday, May 20, 2019 in New York. Jay Saccaro, Baxter’s chief financial officer, is scheduled to present at 1:00 p.m. Eastern Time.